Empirical Validation of Risk Screening for Down's Syndrome

Abstract

Objective—

To validate individual risk estimates in antenatal serum screening for Down's syndrome.

Methods—

Women screened for Down's syndrome using maternal serum a fetoprotein (AFP), unconjugated oestriol (uE₃), and human chorionic gonadotrophs (hCG) with maternal age (the triple test) or AFP, uE₃, free β subunit and free a subunit of hCG with maternal age (the quadruple test) were grouped according to their predicted risk of having an affected pregnancy. The mean predicted risk in each category was then compared with the observed prevalence based on the number of affected and unaffected pregnancies in each category.

Subjects—

About 100 000 pregnant women screened for Down's syndrome from 1989 to 1995.

Results—

There was close agreement between the predicted term risk and the prevalence at birth for both the triple test and the quadruple test. For example, with the quadruple test the predicted risk in the highest risk group was 1 in 3.3 and the prevalence was 1 in 2.6; in the lowest risk group these were 1 in 3000 and 1 in 2300 respectively.

Conclusion—

Risk estimates based on multiple marker screening for Down's syndrome are accurate. The technique used to demonstrate this is simple and offers a useful empirical check on screening performance.

Keywords

Down's syndrome screening validation risk screening serum screening antenatal screening

References

Wald

Cuckle

Densem

Maternal serum screening for Down's syndrome in early pregnancy. BMJ, 1988;297:883–7.

Cavalli

. False negative results in Down's syndrome screening. Lancet, 1996;347:965–6.

Wald

Densem

Smith

Klee

GG.

Four marker serum screening for Down's syndrome. Prenat Diagn 1994; 14:707–16.

Cuckle

Wald

NJ.

Screening for Down's syndrome. In: Lilford

ed. Prenatal diagnosis and prognosis., London: Butterworth, 1990:67–92.

Ryall

RG.

Screening News, 1996;3:4–5.

Wald

Kennard

Densem

Cuckle

Chard

Butler

. Antenatal maternal serum screening for Down's syndrome: Results of a demonstration project. BMJ, 1992;305:391–4.

Haddow

Palomaki

Knight

Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med, 1992;327:588–93.

Cuckle

Wald

Thompson

SG.

Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol, 1987;94:387–402.